Durable Efficacy for Drug Preventing Lung Progression in Systemic Sclerosis

(MedPage Today) -- Patients with interstitial lung disease (ILD) related to systemic sclerosis continued to see less progression when treated with nintedanib (Ofev) in the pivotal 100-week SENSCIS trial, researchers said. Among participants who...
Source: MedPage Today Rheumatology - Category: Rheumatology Source Type: news